MOR has been the subject of a number of other research reports. Berenberg Bank restated a hold rating and set a GBX 1,581 ($20.66) price objective on shares of in a report on Tuesday, June 11th. Deutsche Bank cut shares of Mitsubishi Motors from a buy rating to a hold rating in a report on Thursday, May 9th. Goldman Sachs Group cut shares of Metcash from a conviction-buy rating to a neutral rating in a report on Monday, June 24th. Royal Bank of Canada boosted their price objective on shares of from GBX 2,400 ($31.36) to GBX 2,800 ($36.59) and gave the company an outperform rating in a report on Monday, June 24th. Finally, Independent Research set a €96.00 ($111.63) price objective on shares of MorphoSys and gave the company a neutral rating in a report on Thursday, July 4th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of €101.67 ($118.22).
Shares of ETR MOR opened at €100.70 ($117.09) on Tuesday. The firm has a market capitalization of $3.18 billion and a PE ratio of -54.20. The firm’s 50 day moving average price is €87.84. The company has a debt-to-equity ratio of 8.65, a quick ratio of 7.53 and a current ratio of 7.75. MorphoSys has a 52-week low of €76.45 ($88.90) and a 52-week high of €124.90 ($145.23).
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Recommended Story: What is a short straddle?
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.